As a part of a broader investment round, Beyond Air’s subsidiary NeuroNOS has received an initial equity financing of $2m from private investors, aimed at expediting the preclinical development of its small-molecule drug for paediatrics with autism.
Atalanta Therapeutics has secured oversubscribed $97m in Series B financing to propel the Phase I trials of its RNA interference (RNAi) treatments targeting KCNT1-related epilepsy as well as Huntington’s disease.
Cycle Pharmaceuticals has completed the acquisition of Banner Life Sciences, including BAFIERTAM (monomethyl fumarate) product, a US Food and Drug Administration (FDA)-approved treatment for relapsing forms of multiple sclerosis (MS) in the adult population.
Sanofi’s oral bioactive Bruton’s tyrosine kinase (BTK) inhibitor tolebrutinib has gained breakthrough therapy designation from the US Food and Drug Administration (FDA) for treating the adult population with non-relapsing secondary progressive multiple sclerosis (nrSPMS).
Mind Medicine (MindMed) has received the innovation passport designation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its MM120 Orally Disintegrating Tablet (ODT) as a potential treatment for generalised anxiety disorder (GAD).
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to PharmaTher concerning its ketamine abbreviated new drug application (ANDA).
Acumen Pharmaceuticals has announced the extension of its collaboration with Lonza to facilitate the anticipated commercial launch of sabirnetug, a new therapeutic for early Alzheimer's disease (AD).
Sanofi India Limited and Sanofi Healthcare India (together called “Sanofi India”) have entered into an exclusive partnership with Cipla, focusing on the expansion of its central nervous system (CNS) product portfolio in the Indian market.
Guangzhou Fermion Technology (Fermion) has received approval from China’s National Medical Products Administration (NMPA) for its Investigational New Drug (IND) application for FZ008-145.
CuraSen Therapeutics has secured up to $5.8m from the Alzheimer’s Drug Discovery Foundation (ADDF) to progress CST-3056 for the treatment of Alzheimer’s disease.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.